Opportunity for Investors of PepGen Inc.
Investors who purchased shares of PepGen Inc. are invited to take part in a class action lawsuit concerning alleged securities fraud. The lawsuit has been initiated by The Schall Law Firm, a recognized leader in shareholder rights litigation.
Case Details and Significance
This class action lawsuit focuses on numerous claims against PepGen Inc., also known as "the Company", for purported violations of important securities regulations. The accusations specifically reference breaches of §10(b) and §20(a) within the Securities Exchange Act of 1934, along with Rule 10b-5 established by the U.S. Securities and Exchange Commission.
Timing and Class Period
Investors who bought the Company's securities between the dates of March 7, 2024, and March 3, 2025, are strongly encouraged to reach out to The Schall Law Firm before the deadline of August 8, 2025, for potential participation in the case.
Your Rights as a Shareholder
If you are a shareholder who may have suffered financial losses due to these allegations, it is vital to consider joining this class action to seek recovery. Interested parties can get in touch with The Schall Law Firm for a confidential discussion regarding their legal rights at no cost.
Allegations Against PepGen
The crux of the complaint alleges that PepGen misrepresented critical information to investors. Specifically, the safety and efficacy of PepGen's drug candidate, PGN-EDO51, were called into question. Reports suggest that the Company did not adequately provide data setting its CONNECT2 study as a safe and effective path to FDA approval, raising concerns about participant safety.
Possible Impact on Investors
According to the information disclosed, the outcome of PepGen's CONNECT2 study may lead to significant consequences, including halting the study altogether. Such developments could drastically impact the share price, compounding the losses incurred by investors during the stated class period.
Steps to Participate
Potential class members are welcome to join the lawsuit by contacting The Schall Law Firm. They are actively representing investors on this critical matter, making it essential for any injured parties to take swift action to protect their financial interests.
Contact Information
For further inquiries, investors may reach out to Brian Schall at The Schall Law Firm, located at 2049 Century Park East, Suite 2460. The firm's contact number is 310-301-3335. Additionally, they can visit the firm's website at www.schallfirm.com or send an email to bschall@schallfirm.com.
Frequently Asked Questions
What is the class action lawsuit about?
The lawsuit pertains to alleged securities fraud by PepGen Inc., related to false statements about its drug candidate's safety and efficacy.
Who can participate in the lawsuit?
Investors who purchased PepGen Inc. shares between March 7, 2024, and March 3, 2025, may join the class action.
How can I join the lawsuit?
Interested investors should contact The Schall Law Firm to discuss their eligibility and the process to participate.
What should I do if I suffered losses?
If you believe you suffered losses due to the alleged wrongful acts of PepGen, it is crucial to act immediately and consult an attorney.
What is the deadline for joining?
The deadline to join the lawsuit is August 8, 2025, for those who qualify.